Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 7, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.8K

Pomalidomide.

Monika Engelhardt1,2, Stefanie Ajayi3,4, Heike Reinhardt3

  • 1Hematology and Oncology, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. monika.engelhardt@uniklinik-freiburg.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Nature medicine·2026
Same author

Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.

HemaSphere·2026
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

Performance evaluation of a CD34 expression assay by digital PCR in bone marrow harvest from healthy donors.

Transfusion·2026
Same author

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2026
Same author

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Annals of hematology·2026
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Pomalidomide is an immunomodulatory drug effective against relapsed and refractory multiple myeloma, showing promise in combination therapies for improved patient outcomes. It has demonstrated significant activity in other hematologic malignancies and solid tumors.

Area of Science:

  • Pharmacology and Oncology
  • Immunomodulatory Agents
  • Cancer Therapeutics

Background:

  • Pomalidomide (CC-4047) is a thalidomide derivative with antiangiogenic and immunomodulatory properties.
  • It exhibits potent in vitro antiproliferative and proapoptotic effects.
  • Limited cross-resistance observed between pomalidomide and lenalidomide in vivo.

Purpose of the Study:

  • To review the efficacy and applications of pomalidomide in various hematologic malignancies and solid tumors.
  • To highlight pomalidomide's role in relapsed and refractory multiple myeloma (RRMM).
  • To discuss the development of pomalidomide-based combination therapies.

Main Methods:

  • Review of in vitro and in vivo studies on pomalidomide.
  • Analysis of clinical trial data for pomalidomide in RRMM and other cancers.
Keywords:
Multiple myelomaPomalidomideRelapsed/refractory diseaseTherapy options

Related Experiment Videos

Last Updated: Feb 7, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.8K
  • Examination of regulatory approvals and expanded indications for pomalidomide.

    • Main Results:

    • Pomalidomide shows convincing responses in RRMM patients, including those refractory to lenalidomide and bortezomib.
    • Combination of pomalidomide with low-dose dexamethasone improves responses, progression-free survival (PFS), and overall survival (OS).
    • Pomalidomide demonstrates remarkable activity in AL amyloidosis and myelofibrosis (MF).

    Conclusions:

    • Pomalidomide is a potent therapeutic agent for RRMM and other hematologic malignancies.
    • Triplet combinations involving pomalidomide are being actively investigated for enhanced efficacy.
    • Pomalidomide's established efficacy has led to regulatory approvals and expanded clinical use.